Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Yoshifumi Uwamino is active.

Publication


Featured researches published by Yoshifumi Uwamino.


Helicobacter | 2016

Clinical Features of Community-Acquired Helicobacter cinaedi Bacteremia.

Yoshifumi Uwamino; Kiyoharu Muranaka; Ryota Hase; Yoshihito Otsuka; Naoto Hosokawa

There are growing numbers of reports concerning the clinical and pathological features of Helicobacter cinaedi (H. cinaedi) bacteremia; however, few reports have discussed the features of this condition in healthy individuals.


Respirology | 2016

Middle-aged to elderly women have a higher asymptomatic infection rate with Mycobacterium avium complex, regardless of body habitus

Yukiko Fujita-Suzuki; Masaaki Mori; Stephen M. Carpenter; Hiroshi Fujiwara; Yoshifumi Uwamino; Eiko Tamizu; Ikuya Yano; Hiroshi Kawabe; Naoki Hasegawa

Mycobacterium avium complex (MAC) pulmonary disease is prevalent in middle‐aged to elderly women with a thin body habitus. By comparing the rate of serologically diagnosed asymptomatic MAC infection and body mass index among 1033 healthy subjects, we find that middle‐aged to elderly women became infected with MAC, regardless of their body habitus.


Respiratory Medicine | 2018

Aspergillus precipitating antibody in patients with Mycobacterium avium complex lung disease: A cross-sectional study

Shoji Suzuki; Ho Namkoong; Satoshi Okamori; Kazuma Yagi; Hirofumi Kamata; Yoshifumi Uwamino; Yohei Funatsu; Yasushi Nakano; Tamotsu Ebihara; Tomoko Betsuyaku; Naoki Hasegawa

RATIONALE Little is known about the role of Aspergillus precipitating antibody (APAb) in patients with Mycobacterium avium complex lung disease (MAC-LD). OBJECTIVES We investigated the clinical characteristics of patients with MAC-LD positive for APAb. METHODS We conducted a cross-sectional study targeting patients with MAC-LD. APAb was checked in all participants. Clinical variables included laboratory data, pulmonary function, high-resolution computed tomography findings, and health-related quality of life. RESULTS We analyzed 109 consecutive patients. Their median age was 68 years, and the median duration of MAC-LD was 4.8 years. Twenty (18.3%) patients tested positive for APAb. APAb-positive patients had significantly longer duration of MAC-LD (9.4 vs. 4.0 years, P = 0.017), more severe bronchiectasis evaluated by modified Reiff score (6.5 vs. 4, P = 0.0049), and lower forced expiratory volume in 1 s (%FEV1) (75.1% vs. 86.2%, P = 0.013) than APAb-negative patients. Analysis of covariance adjusted for background factors and underlying pulmonary disease revealed that %FEV1 was also significantly lower in patients with APAb (P = 0.045). Ten patients were newly diagnosed with chronic pulmonary aspergillosis (N = 5) or allergic bronchopulmonary aspergillosis (N = 5). CONCLUSIONS APAb is associated with lower pulmonary function, and observed especially in patients with longer duration of MAC-LD and severe bronchiectasis, even in the absence of cavitary lesions.


International Journal of Infectious Diseases | 2018

Clinical characteristics of pulmonary Mycobacterium lentiflavum disease in adult patients

Kazuma Yagi; Kozo Morimoto; Ho Namkoong; Satoshi Okamori; Shoji Suzuki; Takahiro Asami; Yoshifumi Uwamino; Yohei Funatsu; Hiroshi Fujiwara; Hirofumi Kamata; Tomoko Betsuyaku; Atsuyuki Kurashima; Naoki Hasegawa

BACKGROUND Mycobacterium lentiflavum is a slow-growing non-tuberculous Mycobacterium that is often associated with an immunocompromised state and cervical lymphadenitis in young children. However, little is known about the clinical importance of pulmonary infection with M. lentiflavum in adults. METHODS The medical records of all adults who met the diagnostic criteria of pulmonary M. lentiflavum disease at Keio University Hospital and Fukujuji Hospital from 2001 to 2015 were reviewed. In addition, the PubMed database was searched to identify further reported cases in non-HIV adults. RESULTS Five cases of pulmonary M. lentiflavum disease were identified in the medical records search and 11 additional cases were identified in the literature review. Eleven of the total 16 cases were female, and 15 of 16 cases showed a nodular/bronchiectatic pattern on chest computed tomography imaging. No cases showed an aggressive clinical course of pulmonary M. lentiflavum disease, although one patient died of an exacerbation of underlying vasculitis and bacterial pneumonia. CONCLUSIONS The clinical characteristics of pulmonary M. lentiflavum disease in adult patients were identified. This disease mainly affects females, displays a nodular/bronchiectatic pattern on chest computed tomography imaging, and does not demonstrate an aggressive clinical course. Further larger studies are needed to reveal detailed clinical features.


Internal Medicine | 2017

The first case report of acute cholangitis and bacteremia due to Neisseria subflava

Yoshifumi Uwamino; Kayoko Sugita; Eisuke Iwasaki; Hiroshi Fujiwara; Naoki Hasegawa; Satoshi Iwata

We herein report a case of acute cholangitis and bacteremia caused by a commensal Neisseria species, Neisseria subflava, in an 82-year-old man with cholangiocarcinoma. Emergency endoscopic nasobiliary drainage and cefoperazone/sulbactam therapy were effective. Gram negative coccobacilli were isolated from both blood and bile cultures on 5% sheep blood agar. The isolate was identified as N. subflava biovar perflava by mass spectrometry, a sequence analysis of the 16S rRNA, and biochemical testing. Although biliary infections due to commensal Neisseria are extremely rare, this case demonstrates the possibility of its occurrence in patients undergoing bile duct treatment.


Open Forum Infectious Diseases | 2014

681Microscopically Diagnosed Necrotizing Fasciitis: A Series of 29 Patients —Can We Depend on the Macroscopic Findings?

Kiyoharu Muranaka; Naoto Hosokawa; Ryota Hase; Yoshifumi Uwamino; Takahiro Mikawa; Daisuke Suzuki; Shunsuke Uno; Kazuyasu Miyoshi; Koji Fujita; Hiroyuki Suzuki; Yoshihito Otsuka

Patients —Can We Depend on the Macroscopic Findings? Kiyoharu Muranaka, MD; Naoto Hosokawa, MD, PhD; Ryota Hase, MD; Yoshifumi Uwamino, MD; Takahiro Mikawa, MD; Daisuke Suzuki, MD; Shunsuke Uno, MD; Kazuyasu Miyoshi, MD; Koji Fujita, MD; Hiroyuki Suzuki, MD; Yoshihito Otsuka, PhD; Department of Infectious Diseases, Kameda Medical Center, Kamogawa, Chiba, Japan; Center for Infectious Diseases and Infection Control, Keio University, Shinjuku-ku, Tokyo, Japan; Department of Laboratory Medicine, Kameda Medical Center, Kamogawa, Chiba, Japan


Respiratory Research | 2015

Health-related quality of life is inversely correlated with C-reactive protein and age in Mycobacterium avium complex lung disease: a cross-sectional analysis of 235 patients

Yohei Funatsu; Ho Namkoong; Kazuma Yagi; Shoji Suzuki; Takahiro Asami; Tetsuro Kamo; Hiroshi Fujiwara; Yoshifumi Uwamino; Sadatomo Tasaka; Tomoko Betsuyaku; Naoki Hasegawa


BMC Infectious Diseases | 2017

The efficacy, safety, and feasibility of inhaled amikacin for the treatment of difficult-to-treat non-tuberculous mycobacterial lung diseases

Kazuma Yagi; Ho Namkoong; Takahiro Asami; Osamu Iketani; Shoji Suzuki; Hiroaki Sugiura; Yoshitake Yamada; Hiroshi Fujiwara; Yohei Funatsu; Yoshifumi Uwamino; Tetsuro Kamo; Sadatomo Tasaka; Tomoko Betsuyaku; Naoki Hasegawa


Japanese Journal of Infectious Diseases | 2017

Rapid detection and typing of carbapenemase genes from carbapenem-resistant enterobacteriaceae isolates collected in a Japanese hospital using the Xpert Carba-R assay

Yoshifumi Uwamino; Kayoko Sugita; Naoki Hasegawa; Hiroshi Fujiwara; Satoshi Iwata


The Journal of the Japanese Association for Infectious Diseases | 2013

[Plasmodium malariae malaria with more than a 4-month incubation period: difficult to distinguish from a relapse of Plasmodium vivax malaria].

Ryota Hase; Yoshifumi Uwamino; Kiyoharu Muranaka; Kentaro Tochitani; Misa Sogi; Hidetaka Kitazono; Naoto Hosokawa

Collaboration


Dive into the Yoshifumi Uwamino's collaboration.

Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Researchain Logo
Decentralizing Knowledge